
In 2025, the Grattan Institute called on the Federal Government to combat “extreme” specialist fees. The Institute found that an initial consultation with a cardiologist or endocrinologist can cost up to $370, and up to $670 for a psychiatrist. The Government was advised to claw back public subsidies from specialists who charge “extreme” fees.
On average, patients’ bills for specialist appointments add up to $300 a year. This excludes people who were bulk billed for every appointment, but that’s relatively rare: patients pay out-of-pocket costs for two-thirds of appointments with a specialist doctor.
“Increasing GP costs make national headlines, but specialist fees have risen even more – by 73% since 2010,” the Grattan report asserts. The report attracted pushbacks from doctors, with the latest coming from the nation’s ophthalmologists.
I agree with Australian Society of Ophthalmologists (ASO) President Peter Sumich who says the Grattan report is good, but it draws many wrong conclusions. Firstly, that bottlenecks in specialist training are caused by the Colleges. It is the public hospitals that pay for trainees and mentors, and that purse is controlled by governments, not Colleges. The College committees only select the trainees for the places deemed funded and available.
The second issue involves the Medicare rebate. Specialists have blamed out-of-pocket costs on what they see as the inadequate Medicare rebate not keeping pace with the cost of doing business. Grattan said overcharging specialists should have the rebate totally withdrawn.
The ASO says the Medicare rebate is out of date. “It has no meaning in the commercial world,” Dr Sumich said. “It’s been frozen, cut, and has never kept up with inflation or average wages. Therefore, as a metric of a medical service, it is unreferenced and meaningless.” He added that specialist fees reflect real-world costs – wages, insurance, rent, medical technology, and more – and rejected “the implied threat” to remove patient rebates.
Indeed, Medicare rebates since 2010 have failed to keep pace with inflation, growing only 0.5% to 1% annually, with a five-year freeze from 2013 to 2018. The Federal Government increased bulk-billing incentives for GPs in 2023/24 after prior prolonged underinvestment, but clearly this is not enough to right the wrongs of the past or to pay adequate respect to the difficulties faced by GPs in running a practice. Inflation, in contrast, has grown annually at a rate of 2.5-2.6% since 2010.
“The Medicare rebate belongs to the patient, not the doctor. If it is withdrawn by the Government, then specialists would go the way of dentists and charge their own fees regardless,” Dr Sumich warned. “Most patients would be furious if the rebate was withdrawn.”
And so, the debate comes back to the consumer, paying more and doubting they’re receiving value for the money they spend on their health.
Australian ophthalmologists still remember 2009, when then Health Minister Nicola Roxon threatened to halve the Cataract Medicare Fee. But after an ASO-led public campaign titled “Grandma’s not happy” and significant voter backlash, she backed down to a 12% cut. For a few months though, patients were out of pocket on average $600 even though they had private health insurance.
Earlier this year, a day after introducing legislation to publish specialist fees on the Medical Costs Finder (MCF) website, Health Minister Mark Butler said he was considering direct fee regulation of specialists to counter what he described as “spiralling out-of-pocket costs for medical services”.
The Australian Constitution explicitly disallows laws that result in the practical compulsion of doctors to provide a service in a particular way. It seems unfathomable that our noble profession could be subject to government-regulated, mandated policy.
“ While change is inevitable, our profession should not be further regulated and be blamed as a contributor to the cost-of-living crisis, otherwise Church and State may fully separate.
Federal President Dr Danielle McMullen has reiterated that the AMA rightly believes “doctors should charge a fee that meets the cost of delivering their care”. She also notes that people are being forced into the private sector because of inadequate public sector options and delays.
If this legislation is passed, one can envisage some practitioners will run fully private clinics, with patients bearing the consequences. Personally, I would be browsing over and implementing my AMA fee handbook recommendations if this occurred.
While controversial, my question is, should the Government be fighting the cost-of-living crisis by attacking healthcare, or by not spending $300 billion plus on AUKUS submarines or a Tasmanian stadium? (Conflict of interest declaration: My Freo Dockers don’t need any more threats to a premiership.)
While the MCF will empower patients to make informed decisions on their healthcare, should not the same transparency apply to private health insurers? Patients deserve to know what private health insurers are doing with their premium dollars, such as how much goes towards the hospital bed, the cost of prostheses, and how much goes to those who deliver care.
On a positive note, at least the legislation seeks to stamp out product “phoenixing”, where insurers close an existing policy and reopen a near-identical product at a significantly higher price. While change is inevitable, our profession should not be further regulated and be blamed as a contributor to the cost-of-living crisis, otherwise Church and State may fully separate.
Optometrists with a ‘scheduled medicines endorsement’ on their registration can prescribe a range of topical medications (eye drops) to treat conditions such as infections, inflammations and glaucoma. As of March 2025, approximately 79.2% of registered Australian optometrists held this endorsement.
The Optometry Board of Australia has proposed to increase endorsed optometrists’ scope of practice to include oral medications such as antibiotics for bacterial infections; antihistamines for allergic eye disease; antiviral medications such as aciclovir, famciclovir and valaciclovir; and acetazolamide (Diamox) for emergency treatment of angle closure glaucoma.
No extra training would be required. The proposal is designed to reduce waiting times for seeing either a GP or ophthalmologist, and provide patients with greater access to care, especially in rural settings. Federal AMA Vice-President A/Prof Julian Rait warned the proposed changes risk fragmenting patient care and creating confusion about who is responsible for a patient’s overall medication regime.
“Expanding prescribing rights without robust evidence and safeguards undermines the integrity of Australia’s healthcare system,” A/Prof Rait said. “We need a clear distinction between medical and non-medical roles to ensure prescribing remains the responsibility of those
with appropriate training and accountability.”
Australia’s healthcare system currently ranks first overall among comparable countries, according to the Commonwealth Fund Report 2024, as well as coming first for equity and health outcomes. A/Prof Rait said the AMA supported collaborative care models where non-medical prescribers operate in tightly defined scopes under appropriate clinical governance.
“ If this legislation is passed, one can envisage some practitioners will run fully private clinics, with patients bearing the consequences. Personally, I would be browsing over and implementing my AMA fee handbook recommendations if this occurred.
“The AMA believes optometrists should not be permitted to prescribe beyond topical agents under current arrangements,” he said. “We support a medically led model of care that prioritises patient safety over piecemeal expansion of prescribing rights.”
The concern amongst ophthalmologists is that some oral medications have serious side effects including death. (Diamox can cause aplastic anaemia or sulpha allergy anaphylaxis.) Drug interactions are another concern; and without knowledge of systemic interactions, this is a recipe for disaster. The oral medications will not be PBS-funded either, so there are no savings from that end.
The other concern is, will this be a conduit to prescribing even more potent drugs like oral steroid? State legislation is already facilitating pharmacists to act as pseudo-GPs under the guise of freeing up general practice workloads.
The role of allied health in medical management should be limited, otherwise what is the point of our rigorous medical school and post-graduate training? This is not a protectionist opinion, but one that follows our Hippocratic oath of ‘First do no harm’ – something Government and allied health are not bound by.
You're just getting to the good part! Log in to your AMA (WA) member account to continue reading, or join today for full access to exclusive content, member benefits, and more.
Month End Offer is live!
Get up to 40% off on AMAMedius
Sign in using your membership email and date of birth.